aibioAditxt plans 1-for-27 reverse stock split effective May 18
Tickers ADTX
Aditxt, Inc. said it will effect a 1-for-27 reverse split of its common stock at the opening of trading on May 18, 2026. The company says the split is primarily intended to bring it into compliance with Nasdaq's minimum bid price requirement.
Key facts
- Company
- Aditxt, Inc. (OTC: ADTX)
- News type
- Listings
- Primary source
- Aditxt, Inc. 8-K (2026-05-15)
Aditxt, Inc. (Nasdaq: ADTX) announced in a press release dated May 14, 2026 that it will effect a 1-for-27 reverse split of its common stock. The release was filed as an exhibit to a Form 8-K on May 15, 2026. Trading on a post-split basis begins at the opening of trading on the Nasdaq Capital Market on May 18, 2026, under the same symbol, ADTX.
The stockholders approved the reverse split at the company's annual meeting of stockholders held on May 1, 2026. The release says the board of directors determined the final ratio, which is 1-for-27. The company says additional information about the split can be found in its definitive proxy statement, which it filed with the Securities and Exchange Commission on April 3, 2026.
How the split works
Under the split, every 27 shares of issued and outstanding common stock will be exchanged for one share of common stock. Any fractional shares will be rounded up to the next higher whole share.
The release gives the share counts before and after the split. Before the split, the company expects to have approximately 13,773,321 shares outstanding. Immediately after the split takes effect, it expects approximately 510,123 shares of common stock to be issued and outstanding.
The split will also change the CUSIP number for the common stock, which will become 007025869. The release says the number of shares into which outstanding warrants and stock options can be converted or exercised will be adjusted in line with the split, and that their exercise prices will be adjusted as well.
Why the company is doing it
The release says the reverse split is primarily intended to bring the company into compliance with Nasdaq's minimum bid price requirement. The release does not state the bid price that the company has recorded, and it does not give a deadline for compliance.
The company
The company's annual report filed March 31, 2026 says Aditxt was incorporated in Delaware on September 28, 2017, and that its headquarters are in Mountain View, California. The release describes the company as a social innovation platform accelerating promising health innovations.
The annual report says the company's subsidiary Adimune, Inc. was formed in January 2023 to lead its immune modulation therapeutic programs. The lead product candidate, ADI-100, is designed to tolerize against an antigen linked to type 1 diabetes, psoriasis and autoimmune diseases of the central nervous system. In May 2023, Adimune entered into a clinical trial agreement with the Mayo Clinic for studies in Stiff Person Syndrome. The filing says a human trial for that condition is expected to begin in 2026, with enrollment of 10-20 patients.
Financial position
The SEC XBRL financial data draws on the annual report. For the fiscal year ended December 31, 2025, it reports revenue of $3,195, compared with $133,985 for 2024. Research and development expense was $3.2 million for 2025 and $10.9 million for 2024.
The data reports a net income (loss) of negative $43.1 million for 2025 and negative $40.4 million for 2024. Cash from operations was negative $25.7 million for 2025 and negative $16.8 million for 2024. Year-end 2024 cash and cash equivalents were $833,031.
What the split does not change
The split takes effect May 18, 2026 under the same symbol. It changes the share count, not the company's finances. After it, only about 510,123 shares are expected to be outstanding, a very thin base, and the release does not say what the bid price was, set a compliance deadline or say the company expects to regain compliance by a date. Its own forward-looking statements name the ability to regain and maintain compliance with the bid price requirement and other continued listing standards as uncertain. Meanwhile the company lost $43.1 million in 2025 on revenue of $3,195 and used $25.7 million of cash in operations. The human trial of ADI-100 is, in the annual report, still expected to begin in 2026.